Navigation Links
Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Date:4/4/2008

PRINCETON, N.J., April 4, 2008 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Canaccord|Adams Hepatitis C Conference being held on April 9, 2008 at the St. Regis Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company's clinical and preclinical hepatitis C virus (HCV) programs at 11:15 AM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Receives $10 Million of Working Capital
2. Pharmasset Appoints Herbert J. Conrad as a Director
3. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
4. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
5. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset Appoints Michael Rogers as Chief Development Officer
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Pharmasset Accesses up to $30 Million of Working Capital
10. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
11. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... DIEGO and NEWARK, Del. ... , a privately-held regenerative medicine company, and W. ... materials science company, today announced a collaborative research agreement ... novel implantable cell therapy delivery device technologies that provide ... than a decade, ViaCyte has been developing innovative stem ...
(Date:3/29/2017)... March 29, 2017 The Global Microfluidic Chips ... is a specialized and comprehensive study on the existing state of ... , Europe and Asia-Pacific ... East and Africa . ... Browse 172 Tables and Figures, ...
(Date:3/28/2017)... ... ... Franz Inc ., the leading supplier of Semantic Graph Database technology, ... by Bloor Research in its recent Graph Database Market Update report. ... Gruff, it was rated as the easiest product to use.” – Bloor Research , ...
Breaking Biology Technology:
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
Breaking Biology News(10 mins):